Table 3.

Adverse events during and after treatment

CTCAE grade		All patients (n=7)
		Grade 1	Grade 2	Grade 3	Grade 4
Hematologic AEs		3 (42.9)	4 (57.1)	0 (0.0)	0 (0.0)
	WBC increase	1 (14.3)	0 (0.0)	0 (0.0)	0 (0.0)
	WBC decrease	3 (42.9)	3 (42.9)	0 (0.0)	0 (0.0)
	PLT decrease	1 (14.3)	2 (28.6)	0 (0.0)	0 (0.0)
	ALT/AST increase	1 (14.3)	0 (0.0)	0 (0.0)	0 (0.0)
	Albumin decrease	1 (14.3)	0 (0.0)	0 (0.0)	0 (0.0)
	Bilirubin increase	1 (14.3	0 (0.0)	0 (0.0)	0 (0.0)
Non-hematologic AEs		1 (14.3)	1 (14.3)	1 (14.3)	0 (0.0)
	Fever	1 (14.3)	0 (0.0)	0 (0.0)	0 (0.0)
	Pain	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Dermatitis	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Radiation pneumonitis	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Bleeding	0 (0.0)	1 (14.3)*	1 (14.3)†	0 (0.0)

Values are presented as number (%).

CTCAE, common terminology criteria for adverse events; AE, adverse event; WBC, white blood cell; PLT, platelet; ALT, alanine aminotransferase; AST, aspartate aminotransferase.

^*Epistaxis;

^†Gastric varix bleeding.